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ABSTRACT
Thirty-four isolates of pan-resistant Pseudomonas
aeruginosa producing VIM-2 metallo-b-lactamase
(MBL) were detected at a university hospital in
Spain (July 2004-September 2006). Eleven (32%)
patients had clinically signiﬁcant infections, and
three (27%) of these patients died. A single clone
of MBL-producing P. aeruginosa was identiﬁed by
pulsed-ﬁeld gel electrophoresis. A cluster of
isolates associated with the vascular surgery ward
involved ten patients and appeared as a series of
low-grade, sustained and misdiagnosed endemic
infections in the hospital. The identiﬁcation of
MBL-positive P. aeruginosa should be considered
mandatory in the surveillance of pan-resistant
P. aeruginosa and requires a high index of
suspicion in the context of endemic infections
with a low attack rate.
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Resistance to b-lactams, including carbapenems,
in Pseudomonas aeruginosa may result from the
acquisition of various b-lactamases, including
metallo-b-lactamases (MBLs) [1,2]. Although
MBLs were ﬁrst detected in Spain in 2002 [3],
very few MBL-producing P. aeruginosa (MBL-PA)
strains have been found in Spain (0.08% of
P. aeruginosa isolates in a recent multicentre
study) (unpublished results). In the Hospital
Universitari de Bellvitge (Barcelona, Spain),
which is a 900-bed public institution, a cluster of
pan-resistant P. aeruginosa (PR-PA) isolates pro-
ducing MBLs was suspected in the vascular
surgery ward in May 2005. PR-PA isolates were
deﬁned as being resistant to all b-lactam and
ﬂuoroquinolone antibiotics [4]. The phenotype of
these PR-PA isolates, showing high-level resist-
ance to all b-lactams with the exception of
aztreonam, suggested the production of a carba-
penem-hydrolysing MBL. From May 2005
onwards, prospective ward-based and labora-
tory-based surveillance was used to identify
new cases of PR-PA, and clinical samples were
further investigated to identify MBL producers. In
addition, all PR-PA isolates from July 2004 were
screened retrospectively for MBL production, and
the charts of the patients with P. aeruginosa
isolates that carried a transferable MBL gene
(see below) were reviewed retrospectively.
P. aeruginosa was identiﬁed by standard
methods. MICs were initially determined using
the MicroScan automated microdilution system
(Dade International, West Sacramento, CA, USA)
and Etests (AB Biodisk, Solna, Sweden). CLSI
criteria [5] were used to deﬁne resistance. The
double-disk synergy test (DDST), with ceftazi-
dime (30 lg), imipenem (10 lg) and EDTA disks
(1900 lg), was used to screen isolates for MBLs
[6], and the synergy MBL Etest [7] was used to
further assess MBL production. Genes encoding
IMP and VIM MBLs were detected by PCR in all
DDST-positive isolates, using the universal blaIMP
and blaVIM primers IMP-UP, IMP-DN, VIM-B and
VIM-F, respectively [8,9]. To characterise the
MBL, a PCR speciﬁc for blaVIM-2 (the most pre-
valent MBL in southern Europe) and related
genes was performed with two representative
isolates. Primers VIM-2F and VIM-2R [10] were
used to amplify the complete coding sequence of
blaVIM-2, which was then fully sequenced for both
isolates. Typing, using pulsed-ﬁeld gel electro-
phoresis of genomic DNA digested by SpeI, was
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performed for 20 blaVIM-positive P. aeruginosa
isolates, representative of the entire period, with
the results being interpreted as described previ-
ously [11].
Between July 2004 and September 2006, 2363
patients with P. aeruginosa-positive clinical
samples were detected, with 677 (29%) yielding
carbapenem-resistant isolates, of which 34 (5%)
were MBL-producing isolates. Following the
index case, which occurred in May 2005 in the
vascular surgery ward, nine additional cases were
detected prospectively. Prospective surveillance
during the next 12 months revealed successful
control of MBL-PA clustering in the vascular
ward after reinforcement of the use of barrier
precautions. Among 34 cases detected (Fig. 1), 23
(68%) were males (mean age 62 years). All
isolates except one were nosocomial; the commu-
nity-acquired MBL-PA isolate was from a female
aged 71 years, with a chronic lung disease. The
mean length of stay before isolation of MBL-PA
was 35.6 days. Eleven (32%) patients were infec-
ted and 23 (68%) were colonised. Of the 11
infected patients, two received antibiotic therapy
alone; evaluation of the efﬁcacy of the antimicro-
bial therapy in the remaining nine cases was
complicated by concomitant surgical drainage
(Table 1). The overall mortality rate was 27%,
and only one death was related to the infection as
a result of multi-organ failure secondary to
respiratory tract infection.
The 34 isolates were highly resistant to imipe-
nem (MIC >256 mg ⁄L) and meropenem
(MIC >32 mg ⁄L). All isolates also demonstrated
resistance to all cephalosporins, penicillins,
aminoglycosides and ﬂuoroquinolones, but were
uniformly susceptible to colistin. MICs of aztreo-
nam were lower, although ten isolates showed
resistance (MIC >8 mg ⁄L). All isolates selected,
one for each patient, showed a synergic inhibition
zone with the DDST, and a decrease in imipenem
MIC was observed in the presence of EDTA with
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Fig. 1. Number of patients colonised or infected with metallo-b-lactamase producing Pseudomonas aeruginosa (MBL-PA).
ICU, intensive care unit.
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the MBL Etest. Positive PCR results were obtained
with the VIM primers, and sequencing conﬁrmed
the presence of blaVIM-2. An identical pulsed-ﬁeld
gel electrophoresis proﬁle was found for all 20
isolates tested, including the community-acquired
MBL-PA isolate.
The observation of a cluster of cases involving
MBL-PA isolates among vascular surgery patients
revealed the presence of a low-level, insidious
and sustained monoclonal endemic of MBL-PA
isolates throughout the various wards of the
hospital, including the intensive care units, over
a relatively long period. To date, P. aeruginosa
isolates with acquired MBL determinants have
usually occurred sporadically or have caused
small nosocomial outbreaks [8,10,12], while longi-
tudinal surveys have demonstrated a variable
level of endemicity of MBL producers [13].
VIM-2 was ﬁrst identiﬁed in P. aeruginosa
isolates in southern France [10], and is the most
frequently acquired MBL worldwide. Similar
VIM-producing P. aeruginosa strains have been
described in other areas of Europe in recent years
[3,14–18]. However, to our knowledge, this study
is the ﬁrst report of a cluster of infections caused
by MBL-producing P. aeruginosa in Spain. The
similarity of the pan-resistant phenotype to that
found in many non-MBL-PA isolates in the same
hospital complicates the detection of MBL-pro-
ducing isolates; it was not until the emergence of
a cluster of cases in the vascular surgery ward
that it was apparent that there was an insidious
sustained monoclonal endemic occurring in the
hospital.
The clinical consequences of the endemic were
probably only moderate, as has been suggested
previously [19,20], based on the low (30%)
prevalence of infected patients and an overall
mortality rate of <30% in a population with
severe co-morbid illness. However, the multi-
resistant MBL-PA isolates create important thera-
peutic problems and are associated with high
rates of morbidity.
In conclusion, the identiﬁcation and surveil-
lance of MBL-PA isolates should not be consid-
ered trivial. The difﬁculty of their identiﬁcation
in an outbreak setting, or in an endemic setting
with a low attack rate, requires a high index
of suspicion and the systematic inclusion of
DDST and genotyping studies in nosocomial
surveillance programmes for multiresistant
P. aeruginosa.
Table 1. Clinical characteristics and outcome of 11 patients with infections caused by Pseudomonas aeruginosa isolates
producing metallo-b-lactamase
Patient Date
Diagnosis at
admission
Duration (days) of
previous antibiotic treatment Source
Empirical antibiotic
treatment
Non-antibiotic
treatment
Deﬁnitive antibiotic
treatment Outcome
1 July 2004 Vascular
illness
CIP (20)
AMC (5)
Vascular
prosthesis,
blood
None Removal of
prosthesis +
amputation
None Discharged
2 August 2004 Liver
transplantation
ATM (5) Catheter
vascular
blood
TZP + AMK Removal of
catheter
None Death
(30 days)
3 September 2004 Vascular
illness
None Surgical
wound
CIP Amputation None Discharged
4 October 2004 Joint
illness
CIP (11) Prosthesis,
knee
None Surgical
drainage
ATM Relapse
5 March 2005 Liver
transplantation
ATM (6)
MEM (7)
BAL ﬂuid
specimen
MEM + AMK – – Death
(1 day)
6 April 2005 Vascular
illness
AMC (10) Bone None Finger
amputation
None Death
(45 days)
7 June 2005 Vascular
illness
Chronic
renal
failure
CIP (15) Surgical
wound
IMP Amputation TZP Discharged
8 June 2005 Vascular
illness
TZP (12) Bone None Non-surgical
drainage
TZP Discharged
9 September 2005 Vascular
illness
CIP (23) Bone None – ATM Discharged
10 November 2005 Multiple
trauma
CAZ(15)
IMP (14)
Urine TZP Removal of
urinary
catheter
TZP Discharged
11 September 2006 Oesophageal
perforation
TZP (23)
MEM (8)
IMP (12)
Intra-abdominal
abscess
IMP Surgical
drainage
AMK
ATM
Discharged
CIP, ciproﬂoxacin; AMC, amoxycillin–clavulanic acid; ATM, aztreonam; MEM, meropenem; TZP, piperacillin–tazobactam; CAZ, ceftazidime; IMP, imipenem; AMK,
amikacin.
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